Responding to what it calls “a challenging environment,” AstraZeneca PLC is laying off 24% of its U.S. sales leadership and reps, which translates to eliminating 1,150 positions as of February 2012.
AstraZeneca To Lay Off 24% Of U.S. Sales Force As Of Feb. 2012
The company isn’t providing much detail on reasons or commercial strategy going forward, but its long-term outlook, particularly in western markets, is uninspiring, burdened by generic competition and a mixed R&D track record.